EP1095011A1 - Novel fluorescent lanthanide chelates - Google Patents

Novel fluorescent lanthanide chelates

Info

Publication number
EP1095011A1
EP1095011A1 EP99932334A EP99932334A EP1095011A1 EP 1095011 A1 EP1095011 A1 EP 1095011A1 EP 99932334 A EP99932334 A EP 99932334A EP 99932334 A EP99932334 A EP 99932334A EP 1095011 A1 EP1095011 A1 EP 1095011A1
Authority
EP
European Patent Office
Prior art keywords
group
dtpa
iii
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99932334A
Other languages
German (de)
French (fr)
Other versions
EP1095011A4 (en
Inventor
George Wai-Kin Chan
Robert P. Hertzberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1095011A1 publication Critical patent/EP1095011A1/en
Publication of EP1095011A4 publication Critical patent/EP1095011A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0026—Acridine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C331/00—Derivatives of thiocyanic acid or of isothiocyanic acid
    • C07C331/16—Isothiocyanates
    • C07C331/28—Isothiocyanates having isothiocyanate groups bound to carbon atoms of six-membered aromatic rings

Definitions

  • the present invention relates to the identification and preparation of organic agents that can complex lanthanide cations.
  • this invention relates to complexing agents which contain novel photosensitizers and can produce long-lived fluorescence for use in bioaffinity assays, especially HTRF (homogeneous time-resolved fluorescence) assays.
  • HTRF homogeneous time-resolved fluorescence
  • a wide variety of bioassays are used in the pharmaceutical industry to identify drug development candidate compounds. Recent advances in the identification of pharmaceutical targets, together with the vastly increased output of new compounds using techniques such as combinatorial chemistry have created a need to increase bioassay throughput (number of samples measured per unit time) drastically to meet discovery objectives.
  • Robotics, miniaturization and homogeneous assay formats have all been incorporated into high throughput screening (HTS) assays to increase throughput.
  • HTS high throughput screening
  • an analytical technique suitable for both miniaturization and homogeneous assay formats must provide maximal detection sensitivity and interaction in situ, while requiring only minimal assay time and liquid handling (e.g., separation and filtration).
  • Present analytical techniques, such as those which use radiolabels are unsatisfactory for HTS use because they lack sensitivity, require large sample size and manual liquid handling.
  • fluorescent labels Compared to traditional radiolabels, fluorescent labels have more desirable lifetime, solubility and sensitivity properties for use in HTS assays.
  • the unique lifetime properties of fluorescent labels also meet the needs of fluorescence polarization (FP) and fluorescence correlation spectroscopy (FCS) in the investigation of slow rotational and translational changes in macromolecules.
  • FP fluorescence polarization
  • FCS fluorescence correlation spectroscopy
  • lanthanide chelates have been developed as fluorescence agents for use in the bioassay field. These lanthanide chelates have been reviewed. See Dickson, J. Photochemistry and Photobiology, 27 (1995) 3-19; and Mathis, J. Clinical Ligand Assay 20 (1997) 141-145.
  • the lanthanide chelates are capable of producing long-lived and long wavelength fluorescent emissions upon excitation. In time-delay measurements, they have demonstrated clear advantages over conventional fluorescent labels, in particular less quenching and background interference, while exhibiting increased detection sensitivity.
  • lanthanide chelates have demonstrated superior solubility properties and are able to efficiently transfer energy from their excited states to neighboring acceptor molecules. These advantages render lanthanide chelates ideal agents for HTRF use, especially for developing high-throughput automated and miniaturized binding assays, inncluding immunoassays, DNA hybridization assays, receptor binding assays, enzyme assays, cell-based assays, immunocytochemcial or immunohistochemical assays.
  • lanthanide e.g. terbium, europium
  • Table I three classes of lanthanide chelates, exemplified by the compounds shown in Table I below, are considered to be useful in HTRF:
  • DTPA Chelates (Berkeley) diethylenetriamine-pentaacetic acid type; i.e.
  • PMDA Chelates (Wallac) pyridylmethylamine-diacetic acid type; i.e. These chelates have been described as having chemical stability, long-lived fluorescence (greater than 0.1 ms lifetime) after bioconjugation and significant energy- transfer in specific bioaffinity assays.
  • US5162508, issued to Lehn, et al. on November 10, 1992 discloses bipyridine cryptates.
  • Polycarboxylate chelators with TEKES type photosensitizers (EP 0203047 Al) and te ⁇ yridine type photosensitizers (EP 0649020 Al) are known.
  • WO 96/00901 of Selvin et al. having an International Publication Date of January 11, 1996, discloses diethylenetriaminepentaacetic acid (DTPA) chelates which used carbostyril as sensitizer.
  • DTPA diethylenetriaminepentaacetic acid
  • Bailey, et al., Analyst, 109, (1984) 1449; Ando, et al. Biochim. Biophys. Acta. 1102, (1992) 186; and Heyduk et al., Anal. Biochemistry, 248, (1997) 216 also describe DTPA lanthanide chelates which contain different sensitizers. Additional DTPA chelates with other sensitizers and other tracer metals are known for diagnostic or imaging use (e.g., EP 0450742 Al).
  • the lanthanide chelates provided by the present invention include novel sensitizers which differ from carbostyril and other known chelates. More specifically, these novel sensitizers impart onto the present chelates advantageous physicochemical properties pertaining to excitation wavelength, lifetime, quantum yield, quenching effect, complex stability, photostability, solubility, charge, nonspecific protein interaction, biocoupling efficiency and ease of preparation. Such advantages are desirable to provide a diversity of novel fluorescent probes for use in, and development of, HTRF assays.
  • An object of the present invention is to provide novel lanthanide chelate compounds, and a method for using such compounds in fluorescence detection-based techniques or bioassays. Accordingly, in the first aspect, this invention provides a compound according to
  • this invention provides a method for using the compounds of Formula I in fluorescence detection-based techniques or bioassays.
  • this invention provides a kit for fluorescence detection-based techniques or bioassays which use the compounds of Formula I as the basis for signal detection and measurement.
  • Each compound of the present invention comprises four functional parts: a lanthanide metal cation (e.g. Tb III, Eu III, Sm III, Dy III), a chelator for the lanthanide metal, a photosensitizer for photoexcitation and energy transfer, and a linker for bioconjugation to the target biomolecule, that is, the biomolecule being measured using a fluorescence detection -based spectroscopic technique or bioassay.
  • a lanthanide metal cation e.g. Tb III, Eu III, Sm III, Dy III
  • a chelator for the lanthanide metal e.g. Tb III, Eu III, Sm III, Dy III
  • a photosensitizer for photoexcitation and energy transfer e.g., a photosensitizer for photoexcitation and energy transfer
  • a linker for bioconjugation to the target biomolecule that is, the biomolecule being measured using a fluorescence detection -based spectroscopic technique or bio
  • the present invention provides compounds of Formula I:
  • DTPA diethylenetriaminepentaacetic acid
  • TTHA triethylenetetraaminehexaacetic acid
  • DTPA a polyaminocarboxylate derivative of DTPA or TTHA, preferably DTPA, which chelates a lanthanide metal cation, preferably selected from the group consisting of: Tb III, Eu III, Sm III, and Dy III.
  • the sensitizer Rl is usually related to an aromatic or heteroaromatic amine whose chromophore plays a vital role in excitation and energy transfer. Superior sensitizers usually have highly conjugated systems and an added capacity for lanthanide complexation. We have found several sensitizers, belonging to two structural classes- phenones and quinolines - that provide highly fluorescent compounds of Formula I. Rl is more preferably selected from the following group: aminoacetophenones (AAP), aminobenzophenones (ABP), aminofluorenones (AF), aminoxantones (AX), amino- azaxanthones (AAX), aminoanthraquinones (AAQ), and aminoacridones (AAC):
  • AAP aminoacetophenones
  • ABSP aminobenzophenones
  • AF aminofluorenones
  • AX aminoxantones
  • AAX amino- azaxanthones
  • AAQ aminoanthraquinones
  • AAC aminoacridon
  • R3 and R4 are independently selected from the group consisting of: H, OH, NH2, COCH3, COPh, OPh, NHPh, CN, N0 2 , C0 2 H, C0 CH 3 , 1, Br and Cl.
  • Sensitizers of the present invention belonging to the quinoline class can be further categorized into 3- aminoquinolines (3AQ), and 6-aminoquinolines (6AQ).
  • Rl is selected from the group consisting of:
  • R3 and R4 are as defined herein above.
  • the linker R2 is an amine or other moiety having a functional group that can bioconjugate or can be derivatized to couple with biomolecules.
  • R2 is selected from the group consisting of: OH, NH(CH 2 ) n OH, NH(CH2) n NH 2 , NH(CH 2 ) n PhNH 2 , NH(CH 2 ) n PhOH, NHCH(C02H)CH 2 PhNH 2) , NH(CH2) n PhNCS; wherein n is 1-12.
  • the present invention also contemplates the use of other linkers known in the art for coupling.
  • Particularly preferred compounds of the present invention include the DTPA chelates listed in Table II below:
  • TTHA Triethylene-tetramine-hexaacetic acid
  • More particularly preferred compounds of the present invention include the DTPA chelates below:
  • Sensitizer and chelator moiety abbreviations are as defined in Table II above.
  • bioconjugate and “bioconjugatable” mean the ability of a functional group or groups on a chemical moiety to form covalent linkage to biomolecules.
  • polycarboxylate derivative of DTPA or TTHA means a compound which differs from DTPA and TTHA by changing the length of N-acetic acid units, or by rearranging the units from a linear to a cyclic form.
  • bioassay means immunoassays, DNA hybridization assays, receptor binding assays, enzyme assays, cell-based assays, immunocytochemcial or immunohistochemical assays and the like.
  • the sensitizers and space linkers with structures described herein above are employed in a manner shown in Scheme I and in the Examples.
  • the first step in the synthetic route involves reacting the sensitizer amine, hereby exemplified by 3- aminoacetophenone, with equal or higher molar ratio of DTPAA (diethylene-triamine- pentaacetic anhydride) in the presence of triethylamine.
  • DTPAA diethylene-triamine- pentaacetic anhydride
  • the product formed is not isolated but allowed to react with an equal or a slight molar excess of the linker amine, hereby exemplified by 4-aminophenethylamine.
  • the disubstituted derivative is then isolated and purified by HPLC before converting the linker amino group into a bioconjugatable function.
  • the final step is to react the product (Compound 5) with thiophosgene in a slightly acidic condition to form the isothiocyanate (Compound 6).
  • a chlorotirazine derivative instead of an isothiocyanate can also be prepared from Compound 5 for facile labelling of target molecules with a reactive amino function.
  • the compounds of this invention can be used for labelling donor peptides, proteins,
  • bioassays can be also formated for ultrasensitive high-throughput screening assays.
  • the lanthanide chelate is excited in a fluorescence instrument and provide energy transfer to an acceptor molecule such as an organic dye (e.g. allophycocyanin (APC), or indodicarbocyanin or CY-5) capable of providing the desired long-lived fluorescense emission for quantitation.
  • an organic dye e.g. allophycocyanin (APC), or indodicarbocyanin or CY-5
  • the present invention also provides a method for using the compounds of Formula I in fluorescence detection-based techniques or bioassays.
  • the present method comprises the steps of:
  • a suitable organic dye preferably selected from the group consisting of: allophycocyanin (APC) and indodicarbocyanin (CY-5), to the labelled biomolecule assay sample;
  • Fluorescence instruments suitable for use in the inventive method include the Photon Technology International, Model LS-100, Luminescence System.
  • the present invention further provides a kit for fluorescence detection-based techniques or bioassays which use the compounds of Formula I as the basis for signal detection and measurement, such kit comprising:
  • organic dye preferably selected from the group consisting of: allophycocyanin (APC), indodicarbocyanin (CY-5) and rhodamine.
  • kit provides instructions for proper use thereof, including the appropriate amounts of the compound of Formula I and the organic dye to use for a particular bioassay sample molecular type and size.
  • FTIR Fourier transform infrared
  • Example 2 Preparation of 4AAP-DTPA-APEA-ITC (6).
  • 4AAP-DTPA-APEA 3, 12 mg, 0.019 mmol
  • thiophosgene 85% in CCI4
  • the two phase reaction was allowed to stirred vigorously for 1 h .
  • the mixture was worked up by separating the layers in a separatory funnel and the aqueos solution was washed by additional methylene chloride and then chromatographed on a small reversed-phase C18 column to give the thioisocyanate product (6), an off-white solid in 10 mg yield after lyophilization.

Abstract

The present invention provides complexing agents of Formula (I) which contain novel photosensitizers and produce long-lived fluorescence for use in bioaffinity assays, especially HTRF (homogeneous time-resolved fluorescence) assays.

Description

NOVEL FLUORESCENT LANTHANIDE CHELATES
FIELD OF INVENTION
The present invention relates to the identification and preparation of organic agents that can complex lanthanide cations. In particular, this invention relates to complexing agents which contain novel photosensitizers and can produce long-lived fluorescence for use in bioaffinity assays, especially HTRF (homogeneous time-resolved fluorescence) assays.
BACKGROUND OF THE INVENTION
A wide variety of bioassays are used in the pharmaceutical industry to identify drug development candidate compounds. Recent advances in the identification of pharmaceutical targets, together with the vastly increased output of new compounds using techniques such as combinatorial chemistry have created a need to increase bioassay throughput (number of samples measured per unit time) drastically to meet discovery objectives. Robotics, miniaturization and homogeneous assay formats have all been incorporated into high throughput screening (HTS) assays to increase throughput. Ideally, an analytical technique suitable for both miniaturization and homogeneous assay formats must provide maximal detection sensitivity and interaction in situ, while requiring only minimal assay time and liquid handling (e.g., separation and filtration). Present analytical techniques, such as those which use radiolabels, are unsatisfactory for HTS use because they lack sensitivity, require large sample size and manual liquid handling.
Compared to traditional radiolabels, fluorescent labels have more desirable lifetime, solubility and sensitivity properties for use in HTS assays. The unique lifetime properties of fluorescent labels also meet the needs of fluorescence polarization (FP) and fluorescence correlation spectroscopy (FCS) in the investigation of slow rotational and translational changes in macromolecules.
Traditional fluorescent labels such as organic dyes, e.g., fluoresceins and rhodamines, have long been employed as bioanalytical tools in immunoassays. More recently, lanthanide chelates have been developed as fluorescence agents for use in the bioassay field. These lanthanide chelates have been reviewed. See Dickson, J. Photochemistry and Photobiology, 27 (1995) 3-19; and Mathis, J. Clinical Ligand Assay 20 (1997) 141-145. The lanthanide chelates are capable of producing long-lived and long wavelength fluorescent emissions upon excitation. In time-delay measurements, they have demonstrated clear advantages over conventional fluorescent labels, in particular less quenching and background interference, while exhibiting increased detection sensitivity. In addition to these advantages, many lanthanide chelates have demonstrated superior solubility properties and are able to efficiently transfer energy from their excited states to neighboring acceptor molecules. These advantages render lanthanide chelates ideal agents for HTRF use, especially for developing high-throughput automated and miniaturized binding assays, inncluding immunoassays, DNA hybridization assays, receptor binding assays, enzyme assays, cell-based assays, immunocytochemcial or immunohistochemical assays.
A number of lanthanide (e.g. terbium, europium) complexes are known, but only three classes of lanthanide chelates, exemplified by the compounds shown in Table I below, are considered to be useful in HTRF:
Table I
Cryptates (Packard) bipyridine type; i.e.
DTPA Chelates (Berkeley) diethylenetriamine-pentaacetic acid type; i.e.
PMDA Chelates (Wallac) pyridylmethylamine-diacetic acid type; i.e. These chelates have been described as having chemical stability, long-lived fluorescence (greater than 0.1 ms lifetime) after bioconjugation and significant energy- transfer in specific bioaffinity assays. US5162508, issued to Lehn, et al. on November 10, 1992 discloses bipyridine cryptates. Polycarboxylate chelators with TEKES type photosensitizers (EP 0203047 Al) and teφyridine type photosensitizers (EP 0649020 Al) are known. International Publication No. WO 96/00901 of Selvin et al., having an International Publication Date of January 11, 1996, discloses diethylenetriaminepentaacetic acid (DTPA) chelates which used carbostyril as sensitizer. Bailey, et al., Analyst, 109, (1984) 1449; Ando, et al. Biochim. Biophys. Acta. 1102, (1992) 186; and Heyduk et al., Anal. Biochemistry, 248, (1997) 216 also describe DTPA lanthanide chelates which contain different sensitizers. Additional DTPA chelates with other sensitizers and other tracer metals are known for diagnostic or imaging use (e.g., EP 0450742 Al).
The lanthanide chelates provided by the present invention include novel sensitizers which differ from carbostyril and other known chelates. More specifically, these novel sensitizers impart onto the present chelates advantageous physicochemical properties pertaining to excitation wavelength, lifetime, quantum yield, quenching effect, complex stability, photostability, solubility, charge, nonspecific protein interaction, biocoupling efficiency and ease of preparation. Such advantages are desirable to provide a diversity of novel fluorescent probes for use in, and development of, HTRF assays.
SUMMARY OF THE INVENTION An object of the present invention is to provide novel lanthanide chelate compounds, and a method for using such compounds in fluorescence detection-based techniques or bioassays. Accordingly, in the first aspect, this invention provides a compound according to
Formula I.
In still another aspect, this invention provides a method for using the compounds of Formula I in fluorescence detection-based techniques or bioassays.
In yet another aspect, this invention provides a kit for fluorescence detection-based techniques or bioassays which use the compounds of Formula I as the basis for signal detection and measurement. DETAILED DESCRIPTION OF THE INVENTION
Each compound of the present invention comprises four functional parts: a lanthanide metal cation (e.g. Tb III, Eu III, Sm III, Dy III), a chelator for the lanthanide metal, a photosensitizer for photoexcitation and energy transfer, and a linker for bioconjugation to the target biomolecule, that is, the biomolecule being measured using a fluorescence detection -based spectroscopic technique or bioassay.
The present invention provides compounds of Formula I:
wherein:
[\NΛ]n is a chelator selected from the group consisting of: diethylenetriaminepentaacetic acid (DTPA) (n = 1) or triethylenetetraaminehexaacetic acid (TTHA) (n =2) or a polyaminocarboxylate derivative of DTPA or TTHA, preferably DTPA, which chelates a lanthanide metal cation, preferably selected from the group consisting of: Tb III, Eu III, Sm III, and Dy III.
The sensitizer Rl is usually related to an aromatic or heteroaromatic amine whose chromophore plays a vital role in excitation and energy transfer. Superior sensitizers usually have highly conjugated systems and an added capacity for lanthanide complexation. We have found several sensitizers, belonging to two structural classes- phenones and quinolines - that provide highly fluorescent compounds of Formula I. Rl is more preferably selected from the following group: aminoacetophenones (AAP), aminobenzophenones (ABP), aminofluorenones (AF), aminoxantones (AX), amino- azaxanthones (AAX), aminoanthraquinones (AAQ), and aminoacridones (AAC):
wherein for each nucleus, the amino group NH2 may be attached at one of any possible positions on the phenyl ring. The point of amide attachment to the chelator [\NΛ]n in Formula I may similarly be attached at one of any possible positions on the phenyl ring. R3 and R4 are independently selected from the group consisting of: H, OH, NH2, COCH3, COPh, OPh, NHPh, CN, N02, C02H, C0 CH3, 1, Br and Cl.
Sensitizers of the present invention belonging to the quinoline class can be further categorized into 3- aminoquinolines (3AQ), and 6-aminoquinolines (6AQ). Preferably in the quinoline compounds of the present invention, Rl is selected from the group consisting of:
3AQ 6AQ
wherein R3 and R4 are as defined herein above.
The linker R2 is an amine or other moiety having a functional group that can bioconjugate or can be derivatized to couple with biomolecules. In a preferred embodiment of the present invention, R2 is selected from the group consisting of: OH, NH(CH2)nOH, NH(CH2)nNH2, NH(CH2)nPhNH2, NH(CH2)nPhOH, NHCH(C02H)CH2PhNH2), NH(CH2)nPhNCS; wherein n is 1-12. The present invention also contemplates the use of other linkers known in the art for coupling.
Particularly preferred compounds of the present invention include the DTPA chelates listed in Table II below:
Table II
Formula Rl R2 Lifetime, msec
Lanthanide
Eu Tb
I 3AAP - 0.59 1.73
I 3AQ - 0.59
I 6AQ - 0.60
I 4ABP - 0.60 1.03
I 3AAP 4APEA 0.50 1.62
I 3AAP 4APEA-ITC 0.62 1.65
I 3AAP 4APA 0.60 1.70
I 3AQ 4APEA
I 3AQ CAD
I 6AQ 4APEA
I 6AQ CAD 0.58
I 4ABP 4APEA 0.43 0.73
I 4ABP CAD 0.59 0.82 Abbreviations:
3AAP: 4-aminoacetophenone
3AQ: 3-aminoquinoline
6AQ: 6-aminoquinoline
4ABP: 4-aminobenzophenone
4APEA: 4-aminophenethylamine
4APEA-ITC: 4-isothiocyanatophenethylamine
4APA: 4-aminophenylalanine
DTPA: Diethylene-triamine-pentaacetic acid
TTHA: Triethylene-tetramine-hexaacetic acid
CAD: Cadaverine or 1,5-diaminopentane
More particularly preferred compounds of the present invention include the DTPA chelates below:
7-amino- 1 -azaxanth-5-one 2-amino-xanthone
(7AAX) (2AX)
3-amino-acridone 2-amino-3-cyano-azaxanthone (3AAC) (2ACAX)
2-amino-3-cyano-7-bromo-azaxanthone 2-amino-3-cyano-7-ethyl-azaxanthone (2ACBAX) (2ACEAX)
Definitions Sensitizer and chelator moiety abbreviations are as defined in Table II above.
The terms "bioconjugate" and "bioconjugatable" mean the ability of a functional group or groups on a chemical moiety to form covalent linkage to biomolecules.
The term "polycarboxylate derivative of DTPA or TTHA" means a compound which differs from DTPA and TTHA by changing the length of N-acetic acid units, or by rearranging the units from a linear to a cyclic form.
The term "bioassay" means immunoassays, DNA hybridization assays, receptor binding assays, enzyme assays, cell-based assays, immunocytochemcial or immunohistochemical assays and the like.
Method of Preparation
The sensitizers and space linkers with structures described herein above are employed in a manner shown in Scheme I and in the Examples. The first step in the synthetic route involves reacting the sensitizer amine, hereby exemplified by 3- aminoacetophenone, with equal or higher molar ratio of DTPAA (diethylene-triamine- pentaacetic anhydride) in the presence of triethylamine. The product formed is not isolated but allowed to react with an equal or a slight molar excess of the linker amine, hereby exemplified by 4-aminophenethylamine. The disubstituted derivative is then isolated and purified by HPLC before converting the linker amino group into a bioconjugatable function. The final step is to react the product (Compound 5) with thiophosgene in a slightly acidic condition to form the isothiocyanate (Compound 6). Alternatively, a chlorotirazine derivative instead of an isothiocyanate can also be prepared from Compound 5 for facile labelling of target molecules with a reactive amino function.
a) DTPAA, DMSO, Et3N; b) 4APEA, DMSO, Et3N; c) CSC12, MeCl2-H20
Utility of the Invention The compounds of this invention can be used for labelling donor peptides, proteins,
DNAs, enzyme substrates, ligand molecules in immunoassays, DNA hybridization assays, receptor binding assays, enzyme assays, cell-based assays, immunocytochemcial or immunohistochemical assays and the like. These bioassays can be also formated for ultrasensitive high-throughput screening assays. In the bioassay, the lanthanide chelate is excited in a fluorescence instrument and provide energy transfer to an acceptor molecule such as an organic dye (e.g. allophycocyanin (APC), or indodicarbocyanin or CY-5) capable of providing the desired long-lived fluorescense emission for quantitation.
The present invention also provides a method for using the compounds of Formula I in fluorescence detection-based techniques or bioassays. The present method comprises the steps of:
1. labelling an aliquot comprising donor biomolecules selected from the group consisting of: peptides, proteins, deoxyribonucleic acids (DNAs), ribonucleic acids (RNAs), enzyme substrates, and ligand molecules with a compound of Formula I by a linking reaction with linker R2 to provide a labelled biomolecule assay sample;
2. adding a suitable amount of a suitable organic dye, preferably selected from the group consisting of: allophycocyanin (APC) and indodicarbocyanin (CY-5), to the labelled biomolecule assay sample;
3. exciting the labelled biomolecule assay sample in a suitable fluorescence instrument to provide a fluorescense emission for quantitation.
Fluorescence instruments suitable for use in the inventive method include the Photon Technology International, Model LS-100, Luminescence System. The present invention further provides a kit for fluorescence detection-based techniques or bioassays which use the compounds of Formula I as the basis for signal detection and measurement, such kit comprising:
1. a suitable amount of a compound of Formula I; and
2. a suitable amount of organic dye, preferably selected from the group consisting of: allophycocyanin (APC), indodicarbocyanin (CY-5) and rhodamine.
Such a kit provides instructions for proper use thereof, including the appropriate amounts of the compound of Formula I and the organic dye to use for a particular bioassay sample molecular type and size.
General
Proton NMR spectra were recorded at 400 MHz using a Bruker AMX 400 spectrometer. CDCI3 is deuteriochloroform, DMSO-dβ is hexadeuteriodimethylsulfoxide, and) CD3OD is tetradeuteriomethanol. Chemical shifts are reported in parts per million (d) downfield from the internal standard tetramethylsilane. Abbreviations for NMR data are as follows: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of doublets, dt = doublet of triplets, app = apparent, br = broad. J indicates the NMR coupling constant measured in Hertz. Fourier transform infrared (FTIR) spectra were recorded on a Nicolet Impact 400 D infrared spectrometer. IR and FTIR spectra were recorded in transmission mode, and band positions are reported in inverse wavenumbers (cm"-'). Mass spectra were taken on either VG 70 FE, PE Syx API III, or VG ZAB HF instruments, using fast atom bombardment (FAB) or electrospray (ES) ionization techniques. Examples
In the following synthetic examples, temperature is in degrees Centigrade (°C). Unless otherwise indicated, all of the starting materials were obtained from commercial sources. Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. These Examples are given to illustrate the invention, not to limit its scope. Reference is made to the claims for what is reserved to the inventors hereunder.
Referring to Table II and the Method of Preparation section:
Example 1
Preparation of 3AAP-DTPA (1) and 3AAP-DTPA-4APEA (5)
To a solution of DTPAA (143 mg, 0.4 mmol) in 10 mL dry DMSO and 2 mL dry triethylamine was added a solution of 3-aminoacetophenone (3AAP, 54 mg, 0.4 mmol) in 5 mL DMSO. The mixture was stirred at room temperature for 0.5 h and then treated with a solution of 4-aminophenethylamine (4APEA, 53 mg, 0.4 mmol) in 5 mL DMSO. The mixture was allowed to stir at room temperature for an additional 3 h and then evaporated to dryness. The oily residue was chromatographed on re versed-phase C18 hplc (using a step gradient of 0 to 60% acetonitrile in 0.1% TFA buffer) to give, after lyophilization, 1 as a cream colored solid and 5 as a pale yellow solid. Compound 1 was obtained in 59 mg yield. 1H-NMR (CD OD) : d 2.60 (3H, s), 3.1-3.5 (10H, m), 3.6 (2H, s), 3.65 (2H, s), 3.71 (2H, s), 4.42 (2H, s), 7.42 (1H, dd), 7.75 (1H, dd), 7.83 (1H, dd), 8.31 (1H, d); MS: m/z 511 (M-H), Compound 5 was obtained in 16 mg yield. 1H-NMR (CD30D): d 2.62 (3H, s), 2.73 (2H, t), 3.21 (2H, t), 3.3-3.55 (12H, m), 3.65 (2H, s), 3.74 (2H, s), 4.35 (2H, s), 7.13 (4H, s), 7.41 (1H, dd), 7.75 (1H, dd), 7.83 (1H, dd), 8.32 (lH,d); MS: m/z 682 (M+ 3NH4), 683 (MH+ 3NH4).
Example 2 Preparation of 4AAP-DTPA-APEA-ITC (6). To a solution of 4AAP-DTPA-APEA (3, 12 mg, 0.019 mmol) in 10 mL of 0.5 N HCl was added 4mL of thiophosgene (85% in CCI4). The two phase reaction was allowed to stirred vigorously for 1 h . The mixture was worked up by separating the layers in a separatory funnel and the aqueos solution was washed by additional methylene chloride and then chromatographed on a small reversed-phase C18 column to give the thioisocyanate product (6), an off-white solid in 10 mg yield after lyophilization. H-NMR (CD3OD): 2.60 (3H, s), 2.72 (2H, t), 3.20 (2H, t), 3.3-3.5 (12H, m), 3.65 (2H, s), 3.74 (2H, s), 4.34 (2H, s), 7.12 (4H, s), 7.41 (1H, ss), 7.74 (1H, dd), 7.84 (1H, dd), 8.20 (lH,d); MS: m/z 724 (M+3NH4), 725 (MH+ 3NH4); IR: 2108 cm" 1 (S=C=N stretch).
Example 3 Preparation of 4ABP-DTPA (4) and 4ABP-DTPA-4APEA (12) To a solution of DTPAA (179 mg, 0.5 mmol) in 5 mL of dry DMSO and 3 mL of dry triethylamine was added a solution of 4-aminobenzophenone (4ABP, 99 mg, 0.5 mmol) in 5 mL DMSO. The mixture was stirred for 0.5 h and treated with a solution of 4- aminophenethylamine (4APEA, 68 mg, 0.05 mmol) in 5 mL DMSO. After an additional 3 h stirring at room temperature, the mixture was evaporated to dryness. The oily residue was chromatographed on reversed-phase C 18 hplc (using a step gradietn of 0-60% acetonitrile in 0.1% TFA buffer) to give 4 as a cream colored solid and 12 as a pale yellow solid. Compound 4 was obtained in 57 mg yield. ΪH-NMR (CD3OD): d 3.2-3.5 (10H, m), 3.60 (2H, s), 3.63 (2H, s), 3.74 (2H, s), 4.43 (2H, s), 7.53 (2H, m), 7.62 (1H, dd), 7.76 (2H, m), 7.8 (4H, s); MS: m z 573 (M+H). Compound 12 was obtained in 47 mg yield. H-NMR (CD3OD): d 2.73 (2H, t), 3.25 (2H, t), 3.3-3.5 (12H, m), 3.67 (2H, s), 3.73 (2H, s), 4.3 (2H, s), 7.23 (4H, s), 7.55 (2H, ), 7.64 (1H, dd), 7.8 (2H, m), 7.83 (4H, m); MS: m z 691 (M+H).
The above specification and Examples fully disclose how to make and use the compounds of the present invention. However, the present invention is not limited to the particular embodiments described hereinabove, but includes all modifications thereof within the scope of the following claims. The various references to journals, patents and other publications which are cited herein comprise the state of the art and are incoφorated herein by reference as though fully set forth.

Claims

We claim:
1. A compound of Formula I:
I [\NΛ]n is a chelator selected from the group consisting of: DTPA (n= 1), (TTHA)
(n=2), and a polycarboxylate derivative of DTPA or TTHA, which chelates a lanthanide metal cation;
Rl is selected from the group consisting of: phenones and quinolines; and
R2 is selected from the group consisting of: OH, NH(CH2)nOH, NH(CH2)nNH2)
NH(CH2)nPhNH2, NH(CH2)nPhOH, NHCH(C02H)CH2PhNH2;, NH(CH2)nPhNCS; wherein n is 1-6.
2. A compound according to Claim 1 wherein Rl is selected from the following group: aminoacetophenones (AAP), aminobenzophenones (ABP), aminofluorenones (AF), aminoxantones (AX), amino-azaxanthones (AAX), aminoanthraquinones (AAQ), aminoacridones (AAC), and aminoquinolines (AQ):
wherein R3 and R4 are independently selected from the group consisting of: H, OH, NH2, COCH3, COPh, OPh, NHPh, CN, N02, C02H, and C02CH3.
3. A compound according to Claim 1 wherein Rl is selected from the following group:
7AAX 2AX
3AAC 2ACAX
2ACBAX 2ACEAX
4. A compound according to Claim 1 wherein [\NΛ]n is DTPA (n= 1).
5. A compound according to Claim 1 wherein the lanthanide metal cation is selected from the group consisting of: Tb III, Eu III, Sm III, and Dy III.
6. A compound according to Claim 5 wherein the lanthanide metal cation is selected from the group consisting of: Eu III or Tb III.
7. A method for using a compound of Formula I:
wherein:
[\NΛ]n is a chelator selected from the group consisting of: DTPA (n= 1), (TTHA)
(n=2), and a polycarboxylate derivative of DTPA or TTHA, which chelates a lanthanide metal cation;
Rl is selected from the group consisting of: phenones and quinolines; and
R2 is selected from the group consisting of: OH, NH(CH2)nOH, NH(CH2)nNH2,
NH(CH2)nPhNH2, NH(CH2)nPhOH, NHCH(C02H)CH2PhNH2), NH(CH2)nPhNCS; wherein n is 1-6; in fluorescence detection-based techniques or bioassays comprising the steps of: a. labelling an aliquot comprising donor biomolecules selected from the group consisting of: peptides, proteins, deoxyribonucleic acids (DNAs), ribonucleic acids (RNAs), enzyme substrates, and ligand molecules with a compound of Formula I by a linking reaction with linker R2 to provide a labelled biomolecule assay sample; b. adding a suitable amount of a suitable organic dye to the labelled biomolecule assay sample; c. exciting the labelled biomolecule assay sample in a suitable fluorescence instrument to provide a fluorescense emission for quantitation.
8. A method according to Claim 7 wherein said organic dye is selected from the group consisting of but not limited to: rhodamine, allophycocyanin (APC) and indodicarbocyanin (CY-5),
9. A kit for fluorescence detection-based techniques or bioassays comprising: a. a suitable amount of a compound of Formula I; and b. a suitable amount of organic dye.
10. A kit according to Claim 9 wherein said organic dye is selected from the group consisting of but not limited to: rhodamine, allophycocyanin (APC) and indodicarbocyanin (CY-5).
EP99932334A 1998-07-07 1999-07-07 Novel fluorescent lanthanide chelates Withdrawn EP1095011A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9194498P 1998-07-07 1998-07-07
US91944P 1998-07-07
PCT/US1999/015366 WO2000001663A1 (en) 1998-07-07 1999-07-07 Novel fluorescent lanthanide chelates

Publications (2)

Publication Number Publication Date
EP1095011A1 true EP1095011A1 (en) 2001-05-02
EP1095011A4 EP1095011A4 (en) 2003-01-08

Family

ID=22230424

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99932334A Withdrawn EP1095011A4 (en) 1998-07-07 1999-07-07 Novel fluorescent lanthanide chelates

Country Status (4)

Country Link
EP (1) EP1095011A4 (en)
JP (1) JP2002519404A (en)
CA (1) CA2336904A1 (en)
WO (1) WO2000001663A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440389B1 (en) * 2000-07-19 2002-08-27 The General Hospital Corporation Fluorescent agents for real-time measurement of organ function
JP2004511632A (en) 2000-10-19 2004-04-15 エクソンモービル・ケミカル・パテンツ・インク Cationic group 3 catalyst system
DE10163295B4 (en) 2001-12-21 2004-03-25 Honeywell Specialty Chemicals Seelze Gmbh Rare earth metal compounds and mixtures thereof, processes for their preparation and their use
DE102004022628A1 (en) * 2004-05-07 2005-12-15 Sensient Imaging Technologies Gmbh FRET bioassay
DE102004024011A1 (en) * 2004-05-14 2005-12-01 Bayer Chemicals Ag Difluoro-1,3-dioxole
WO2006014645A1 (en) * 2004-07-23 2006-02-09 Amgen Inc. Generic probes for the detection of phosphorylated sequences
CN101010107A (en) * 2004-08-26 2007-08-01 马林克罗特公司 Luminescent metal complexes for monitoring renal function
EP1885817B1 (en) * 2005-05-11 2016-05-11 University Of Durham Responsive luminescent lanthanide complexes
DK1885817T3 (en) 2005-05-11 2016-08-22 Univ Durham Luminescent lanthanide OF RESPONSE
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
GB2451106A (en) * 2007-07-18 2009-01-21 Cis Bio Int Lanthanide (III) ion complexing pyrazoyl-aza(thio)xanthone comprising compounds, their complexes and their use as fluorescent labels
BR112012008381A2 (en) 2009-09-24 2017-06-13 Inserm (Institut Nat De La Santé Et De La Rech Médicale) fkbp52-tau interaction as a new therapeutic target to treat neurological disorders involving tau dysfunction
WO2011083124A1 (en) 2010-01-05 2011-07-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Flt3 receptor antagonists for the treatment or the prevention of pain disorders
DE102011001368B4 (en) 2011-03-17 2013-01-31 Bundesanstalt für Materialforschung und -Prüfung (BAM) Lanthanoid chelates containing particles, their preparation and their use in bioanalysis
DE102011101207B3 (en) 2011-05-11 2012-05-10 Sartorius Stedim Biotech Gmbh Fluorescent dye for pH sensor
US20140296106A1 (en) 2011-05-16 2014-10-02 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for screening substances capable of modulating the replication of an influenza virus
WO2014053871A1 (en) 2012-10-04 2014-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for screening a compound capable of inhibiting the notch1 transcriptional activity
EP3108255B1 (en) 2014-02-18 2020-08-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of diseases mediated by the nrp-1/obr complex signaling pathway
WO2015158810A1 (en) 2014-04-17 2015-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Polypeptides and uses thereof for reducing cd95-mediated cell motility
US20220098681A1 (en) 2019-01-11 2022-03-31 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for screening inhibitors against chikungunya virus and for determining whether subjects are predisposed to infection by said virus

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162508A (en) * 1987-12-18 1992-11-10 Compagnie Oris Industrie Rare earth cryptates, processes for their preparation, synthesis intermediates and application as fluorescent tracers
WO1996000901A1 (en) * 1994-06-29 1996-01-11 The Regents Of The University Of California Luminescent lanthanide chelates and methods of use
DE19505960A1 (en) * 1995-02-21 1996-08-22 Deutsches Krebsforsch Conjugate for the individual dosage of drugs
WO1999066780A2 (en) * 1998-06-25 1999-12-29 Smithkline Beecham Plc Cinoxacin lanthanide chelates and their use as biomolecular probes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162508A (en) * 1987-12-18 1992-11-10 Compagnie Oris Industrie Rare earth cryptates, processes for their preparation, synthesis intermediates and application as fluorescent tracers
WO1996000901A1 (en) * 1994-06-29 1996-01-11 The Regents Of The University Of California Luminescent lanthanide chelates and methods of use
DE19505960A1 (en) * 1995-02-21 1996-08-22 Deutsches Krebsforsch Conjugate for the individual dosage of drugs
WO1999066780A2 (en) * 1998-06-25 1999-12-29 Smithkline Beecham Plc Cinoxacin lanthanide chelates and their use as biomolecular probes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BAILEY, M.PHILIP ET AL.: ANALYST, vol. 110, 1985, pages 603-604, XP001040544 *
DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; retrieved from STN Database accession no. 127:77478/DN, HCAPLUS XP002219212 & OZAKI, H. ET AL.: KIDORUI, vol. 30, 1997, pages 358-359, *
See also references of WO0001663A1 *

Also Published As

Publication number Publication date
EP1095011A4 (en) 2003-01-08
CA2336904A1 (en) 2000-01-13
WO2000001663A1 (en) 2000-01-13
JP2002519404A (en) 2002-07-02

Similar Documents

Publication Publication Date Title
EP1095011A1 (en) Novel fluorescent lanthanide chelates
JP5335236B2 (en) Lanthanide chelates and their use in bioassays
EP0203047B1 (en) Fluorescent lanthanide chelates
JP5548363B2 (en) Novel fluorescent dyes and their use
US5457186A (en) Luminescent lanthanide chelates with decreased non-radiative energy loss
KR20180132501A (en) Ultra bright dimeric or polymeric dyes
CN106232771B (en) The new chromophore architectures of lanthanide chelate
US6740756B1 (en) Fluorescent lanthanide chelates
US20210395606A1 (en) Chromophoric structures for macrocyclic lanthanide chelates
US6552199B1 (en) Fluorescence dyes and their use as fluorescence markers
Deslandes et al. Synthesis and optical properties of macrocyclic lanthanide (III) chelates as new reagents for luminescent biolabeling
EP1623979A1 (en) Fluorescent lanthanide complex
DE60214709T2 (en) Method for increasing the hydrophilicity of fluorescent marker compounds
US6809220B2 (en) Trityl-type compounds and their use
US6441167B1 (en) Cinoxacin lanthanide chelates and their use as biomolecular probes
Ketola et al. Synthesis of lanthanide (III) chelates by using ‘click’chemistry
US5151517A (en) Derivatives of tetrahydro-2,3,6,7,1h,5h,11h-(1)benzopyrano(6,7,8,i,j)quinolizinone-11 usable as markers for organic compounds, particularly biological compounds with a view to their detection by chemiluminescence or fluorescence
JP2023092930A (en) Diaminobenzene compounds comprising sulfinyl or sulfonyl groups or salts thereof, and organic fluorescent materials having them
Mihaela et al. Synthesis and biological application of a new 1, 2, 5-oxadiazolo [3, 4-c] pyridine moiety fluorescent marker

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010202

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20021126

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20031112

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060822